Engene Holdings Inc (ENGN)

$8.53 +0.10 (1.19%)
Market Cap 444.35M
Revenue (ttm) 0.00
Net Income (ttm) -55.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 1,201,300
Avg Vol 1,411,518
Day's Range N/A - N/A
Shares Out 51.19M
Stochastic %K 50%
Beta -0.27
Analysts Strong Sell
Price Target $22.10

Company Profile

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). enGene Holdings Inc. is based in Montreal, Canada.

Industry: Biotechnology
Sector: Healthcare
Phone: 514 332 4888
Address:
4868 Rue Levy, Suite 220, Montreal, Canada
Dontlookkid
Dontlookkid Nov. 14 at 2:49 PM
$ENGN just send it we know it’s going up
0 · Reply
AAUS1
AAUS1 Nov. 14 at 1:32 PM
$ENGN waiting for a bigger drop
0 · Reply
stoxrgood
stoxrgood Nov. 13 at 8:48 PM
$ENGN how is this dropping??? what about all the $20 and $30 price targets??
0 · Reply
NoTworrieD_
NoTworrieD_ Nov. 13 at 7:30 PM
$ENGN back to $9 then $10
0 · Reply
Dontlookkid
Dontlookkid Nov. 13 at 12:18 PM
$ENGN save the American people and full of sudden today
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Nov. 13 at 12:16 PM
$ENGN flash crash at 4:01 yesterday trigger any one’s else’s stop loss?
0 · Reply
farDoc
farDoc Nov. 12 at 11:03 PM
$ENGN🚨 $ENGN Short Squeeze Setup? 🚨 Short volume just spiked way above normal 👀 — heavy pressure building that could blow if this starts moving up! Indicator shows big short activity vs 7-day avg. Could be primed for a squeeze if momentum flips. 🔥 Just a stupid ape 🦍 thinking I might be on to something or just on something- lol… Not financial advice! $AMC fellow Ape here.
0 · Reply
farDoc
farDoc Nov. 12 at 10:34 PM
$ENGN Could this squeeze? Watching and waiting.
2 · Reply
DonCorleone77
DonCorleone77 Nov. 12 at 9:08 PM
$ENGN enGene announces common shares offering, no amount given
1 · Reply
anachartanalyst
anachartanalyst Nov. 12 at 8:02 PM
$ENGN https://anachart.com/wp-content/uploads/ana_temp/1762977726_soc-img.jpg
0 · Reply
Latest News on ENGN
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

Nov 13, 2025, 12:27 AM EST - 1 day ago

enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants

enGene Announces Proposed Public Offering of Common Shares

Nov 12, 2025, 4:01 PM EST - 2 days ago

enGene Announces Proposed Public Offering of Common Shares

enGene Holdings: Still A Buy After A Massive Surge

Nov 12, 2025, 9:52 AM EST - 2 days ago

enGene Holdings: Still A Buy After A Massive Surge

enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript

Nov 11, 2025, 1:41 PM EST - 3 days ago

enGene Holdings Inc. (ENGN) Discusses Preliminary Data From LEGEND Pivotal Cohort in High-Risk BCG-Unresponsive NMIBC Transcript

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

Nov 11, 2025, 10:37 AM EST - 3 days ago

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

Nov 11, 2025, 7:30 AM EST - 3 days ago

Detalimogene Demonstrates Improved Complete Response Rate of 62% at 6 Months

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

Nov 10, 2025, 4:05 PM EST - 4 days ago

enGene to Host Conference Call to Provide Update on Pivotal Cohort of LEGEND Trial

enGene to Participate in Upcoming Investor Conferences

Nov 6, 2025, 5:00 PM EST - 8 days ago

enGene to Participate in Upcoming Investor Conferences

enGene Named a BioSpace 2026 Best Places to Work Winner

Nov 4, 2025, 1:35 PM EST - 10 days ago

enGene Named a BioSpace 2026 Best Places to Work Winner

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Oct 1, 2025, 4:03 PM EDT - 6 weeks ago

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

Sep 30, 2025, 7:30 AM EDT - 6 weeks ago

enGene Appoints Hussein Sweiti, M.D., MSc, as Chief Medical Officer

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 11, 2025, 4:03 PM EDT - 2 months ago

enGene Reports Third Quarter 2025 Financial Results and Provides Business Update

EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 5:25 PM EDT - 2 months ago

EnGene Holdings Inc. (ENGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Sep 3, 2025, 7:30 AM EDT - 2 months ago

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

Jul 8, 2025, 8:00 AM EDT - 4 months ago

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

Jun 25, 2025, 8:00 AM EDT - 5 months ago

FDA Grants RMAT Designation for enGene's Detalimogene, Enabling Potential for Expedited Review in High-Risk, Non-Muscle Invasive Bladder Cancer

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

Jun 18, 2025, 4:16 PM EDT - 5 months ago

enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 12, 2025, 8:00 AM EDT - 5 months ago

enGene Reports Second Quarter 2025 Financial Results and Provides Business Update

enGene Announces the Resignation of its Chief Medical Officer

Jun 4, 2025, 8:30 AM EDT - 5 months ago

enGene Announces the Resignation of its Chief Medical Officer

enGene to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 6 months ago

enGene to Present at the Jefferies Global Healthcare Conference

enGene Names Amy Pott as Chief Global Commercialization Officer

May 28, 2025, 7:30 AM EDT - 6 months ago

enGene Names Amy Pott as Chief Global Commercialization Officer

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 8:00 AM EDT - 8 months ago

enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 10, 2025, 4:05 PM EDT - 8 months ago

enGene Reports First Quarter 2025 Financial Results and Provides Business Update

enGene to Participate in the Leerink Partners Global Healthcare Conference

Mar 4, 2025, 8:00 AM EST - 9 months ago

enGene to Participate in the Leerink Partners Global Healthcare Conference

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

Feb 27, 2025, 4:20 AM EST - 9 months ago

enGene Holdings Inc.: Unknown Company Which Looks Like A Catch

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 10 months ago

enGene to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

Jan 30, 2025, 8:00 AM EST - 10 months ago

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

Dec 19, 2024, 4:05 PM EST - 11 months ago

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

Dec 15, 2024, 4:53 AM EST - 11 months ago

enGene Holdings: Compelling Early Data Bode Well For Their Near-Term Outlook

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

enGene to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

Oct 25, 2024, 8:00 AM EDT - 1 year ago

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Oct 22, 2024, 4:05 PM EDT - 1 year ago

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Oct 21, 2024, 8:45 AM EDT - 1 year ago

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

Sep 26, 2024, 6:30 AM EDT - 1 year ago

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

Sep 10, 2024, 4:33 PM EDT - 1 year ago

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Jul 24, 2024, 4:05 PM EDT - 1 year ago

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

Jul 24, 2024, 6:30 AM EDT - 1 year ago

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

Jun 14, 2024, 7:01 AM EDT - 1 year ago

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

May 15, 2024, 4:05 PM EDT - 1 year ago

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

May 2, 2024, 4:05 PM EDT - 1 year ago

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

/C O R R E C T I O N -- enGene Inc./

Apr 9, 2024, 8:56 AM EDT - 1 year ago

/C O R R E C T I O N -- enGene Inc./

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

Apr 9, 2024, 8:00 AM EDT - 1 year ago

enGene Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

Mar 11, 2024, 5:16 PM EDT - 1 year ago

enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress

enGene To Present at the Leerink Partners Global Biopharma Conference

Mar 5, 2024, 7:00 AM EST - 1 year ago

enGene To Present at the Leerink Partners Global Biopharma Conference

enGene Holdings: Mid-2024 NMIBC Data Could Lead To EG-70 BLA Filing

Feb 15, 2024, 6:30 PM EST - 1 year ago

enGene Holdings: Mid-2024 NMIBC Data Could Lead To EG-70 BLA Filing

enGene Announces Oversubscribed $200 Million Private Placement Financing

Feb 14, 2024, 6:50 AM EST - 1 year ago

enGene Announces Oversubscribed $200 Million Private Placement Financing

enGene Announces Leadership Succession Plan

Feb 14, 2024, 6:45 AM EST - 1 year ago

enGene Announces Leadership Succession Plan

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

Jan 30, 2024, 7:00 AM EST - 1 year ago

enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

Jan 29, 2024, 7:00 AM EST - 1 year ago

enGene Reports Full Year 2023 Financial Results and Recent Operational Progress

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

Dec 22, 2023, 5:00 PM EST - 2 years ago

enGene Announces Expanded $50 Million Debt Facility with Hercules Capital

HTGC

Dontlookkid
Dontlookkid Nov. 14 at 2:49 PM
$ENGN just send it we know it’s going up
0 · Reply
AAUS1
AAUS1 Nov. 14 at 1:32 PM
$ENGN waiting for a bigger drop
0 · Reply
stoxrgood
stoxrgood Nov. 13 at 8:48 PM
$ENGN how is this dropping??? what about all the $20 and $30 price targets??
0 · Reply
NoTworrieD_
NoTworrieD_ Nov. 13 at 7:30 PM
$ENGN back to $9 then $10
0 · Reply
Dontlookkid
Dontlookkid Nov. 13 at 12:18 PM
$ENGN save the American people and full of sudden today
0 · Reply
ScottyDoesntKnowMeSon
ScottyDoesntKnowMeSon Nov. 13 at 12:16 PM
$ENGN flash crash at 4:01 yesterday trigger any one’s else’s stop loss?
0 · Reply
farDoc
farDoc Nov. 12 at 11:03 PM
$ENGN🚨 $ENGN Short Squeeze Setup? 🚨 Short volume just spiked way above normal 👀 — heavy pressure building that could blow if this starts moving up! Indicator shows big short activity vs 7-day avg. Could be primed for a squeeze if momentum flips. 🔥 Just a stupid ape 🦍 thinking I might be on to something or just on something- lol… Not financial advice! $AMC fellow Ape here.
0 · Reply
farDoc
farDoc Nov. 12 at 10:34 PM
$ENGN Could this squeeze? Watching and waiting.
2 · Reply
DonCorleone77
DonCorleone77 Nov. 12 at 9:08 PM
$ENGN enGene announces common shares offering, no amount given
1 · Reply
anachartanalyst
anachartanalyst Nov. 12 at 8:02 PM
$ENGN https://anachart.com/wp-content/uploads/ana_temp/1762977726_soc-img.jpg
0 · Reply
nbkihy8
nbkihy8 Nov. 12 at 5:39 PM
$ENGN They are coming in now. Will push higher
0 · Reply
Dontlookkid
Dontlookkid Nov. 12 at 5:27 PM
$ENGN send it
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 5:17 PM
Morgan Stanley has updated their rating for enGene Holdings ( $ENGN ) to Overweight with a price target of 19.
0 · Reply
CoolCatTrades
CoolCatTrades Nov. 12 at 4:42 PM
Made huge profit on this guys call, +9k$ Gave @MomentumZeus a FOLLOW . insane trader lol. He called CMCT couple days ago and it just ran 100%+ Watching $BKYI $NUAI $MSGM $ENGN 00
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 4:40 PM
Oppenheimer has updated their rating for enGene Holdings ( $ENGN ) to Outperform with a price target of 33.
0 · Reply
Zackpedia
Zackpedia Nov. 12 at 3:46 PM
$ENGN Selling time again above 9
0 · Reply
CoolCatTrades
CoolCatTrades Nov. 12 at 2:55 PM
Made a killing on this guys call, Gave @MomentumZeus a FOLLOW . Insane trader. He called CMCT couple days ago and it just ran 100%+ Good momentum on $SLRX $ENGN $BW $ANVS also
0 · Reply
marti837
marti837 Nov. 12 at 2:39 PM
$ENGN god give me 11 today
0 · Reply
genicemel14
genicemel14 Nov. 12 at 2:37 PM
$WTF $ENGN
0 · Reply
IBOTTheDipAndTheDipWon
IBOTTheDipAndTheDipWon Nov. 12 at 2:36 PM
The $ENGN definitely seems to be in neutral. OK, the transmission.
1 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 2:27 PM
UBS updates rating for enGene Holdings ( $ENGN ) to Neutral, target set at 4 → 10.
0 · Reply
JarvisFlow
JarvisFlow Nov. 12 at 2:17 PM
Citizens has adjusted their stance on enGene Holdings ( $ENGN ), setting the rating to Market Outperform with a target price of 18 → 21.
0 · Reply